Correction to: Allergy Asthma Clin Immunol (2019) 15:72 https://doi.org/10.1186/s13223-019-0376-8
Following the publication of this article [1], the authors requested to amend the characterisation of ‘lanadelumab’ from ‘humanised’ to the correct ‘fully human’.
Therefore, the fourth paragraph under Recommendation #24 should be amended to read:
Anzeige
“Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP…”
Similarly, the first paragraph under Recommendation #27 should be amended to read:
“Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/κ-light chain)…”
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.